Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder

T. Nishiyama, M. Ikeda, Nakao Iwata, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Sekine, M. Iyo, M. Harano, T. Komiyama, M. Yamada, I. Sora, H. Ujike, T. Inada, T. Furukawa, N. Ozaki

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalPharmacogenomics Journal
Volume5
Issue number2
DOIs
Publication statusPublished - 19-04-2005

Fingerprint

Methamphetamine
GABA-A Receptors
Haplotypes
Schizophrenia
Genes
Single Nucleotide Polymorphism
Aminobutyrates
Linkage Disequilibrium
gamma-Aminobutyric Acid
Case-Control Studies

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Nishiyama, T. ; Ikeda, M. ; Iwata, Nakao ; Suzuki, T. ; Kitajima, T. ; Yamanouchi, Y. ; Sekine, Y. ; Iyo, M. ; Harano, M. ; Komiyama, T. ; Yamada, M. ; Sora, I. ; Ujike, H. ; Inada, T. ; Furukawa, T. ; Ozaki, N. / Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder. In: Pharmacogenomics Journal. 2005 ; Vol. 5, No. 2. pp. 89-95.
@article{7d445a3068834679b17117703d309f99,
title = "Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder",
abstract = "Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.",
author = "T. Nishiyama and M. Ikeda and Nakao Iwata and T. Suzuki and T. Kitajima and Y. Yamanouchi and Y. Sekine and M. Iyo and M. Harano and T. Komiyama and M. Yamada and I. Sora and H. Ujike and T. Inada and T. Furukawa and N. Ozaki",
year = "2005",
month = "4",
day = "19",
doi = "10.1038/sj.tpj.6500292",
language = "English",
volume = "5",
pages = "89--95",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

Nishiyama, T, Ikeda, M, Iwata, N, Suzuki, T, Kitajima, T, Yamanouchi, Y, Sekine, Y, Iyo, M, Harano, M, Komiyama, T, Yamada, M, Sora, I, Ujike, H, Inada, T, Furukawa, T & Ozaki, N 2005, 'Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder', Pharmacogenomics Journal, vol. 5, no. 2, pp. 89-95. https://doi.org/10.1038/sj.tpj.6500292

Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder. / Nishiyama, T.; Ikeda, M.; Iwata, Nakao; Suzuki, T.; Kitajima, T.; Yamanouchi, Y.; Sekine, Y.; Iyo, M.; Harano, M.; Komiyama, T.; Yamada, M.; Sora, I.; Ujike, H.; Inada, T.; Furukawa, T.; Ozaki, N.

In: Pharmacogenomics Journal, Vol. 5, No. 2, 19.04.2005, p. 89-95.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder

AU - Nishiyama, T.

AU - Ikeda, M.

AU - Iwata, Nakao

AU - Suzuki, T.

AU - Kitajima, T.

AU - Yamanouchi, Y.

AU - Sekine, Y.

AU - Iyo, M.

AU - Harano, M.

AU - Komiyama, T.

AU - Yamada, M.

AU - Sora, I.

AU - Ujike, H.

AU - Inada, T.

AU - Furukawa, T.

AU - Ozaki, N.

PY - 2005/4/19

Y1 - 2005/4/19

N2 - Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.

AB - Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.

UR - http://www.scopus.com/inward/record.url?scp=20144389670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144389670&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500292

DO - 10.1038/sj.tpj.6500292

M3 - Article

C2 - 15772696

AN - SCOPUS:20144389670

VL - 5

SP - 89

EP - 95

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -